S&P Futures
5,889.50 -3.00 (-0.05%) Dow Futures
43,047.00 -122.00 (-0.28%) Nasdaq Futures
20,528.50 -13.50 (-0.07%) Russell 2000 Futures
2,245.00 -1.20 (-0.05%) Crude Oil
72.24 +0.15 (+0.21%) Gold
2,753.60 -6.20 (-0.22%)
Lyell Immunopharma, Inc. (LYEL)
After hours:
| Previous Close | 1.1200 |
| Open | 1.0900 |
| Bid | 0.0000 x 0 |
| Ask | 0.0000 x 0 |
| Day's Range | 1.0900 - 1.1700 |
| 52 Week Range | 1.0600 - 3.2560 |
| Volume | |
| Avg. Volume | 637,180 |
| Market Cap | 294.403M |
| Beta (5Y Monthly) | -0.54 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.8300 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 3.67 |
GlobeNewswireLyell Immunopharma Announces the Acceptance Abstracts for Presentation at 2024 Society for Immunotherapy of Cancer (SITC) Annual Meeting
SOUTH SAN FRANCISCO, Calif., Oct. 04, 2024 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical‑stage T-cell reprogramming company advancing a diverse pipeline of cell therapies for patients with solid tumors or hematologic malignancies, announced today that three abstracts highlighting its pipeline of clinical product candidates and anti-exhaustion technology have been accepted for presentation at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) takin
- GlobeNewswire
Lyell Immunopharma Announces Participation in Goldman Sachs Cell Therapy Day
SOUTH SAN FRANCISCO, Calif., Sept. 24, 2024 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical‑stage T-cell reprogramming company advancing a diverse pipeline of cell therapies for patients with solid tumors or hematologic malignancies, announced today that Lynn Seely, MD, Lyell’s President & CEO, will participate on a panel discussion on next-generation cell therapies in oncology at Goldman Sachs Cell Therapy Day on October 1 at 11:50 a.m. ET. A webcast of the presentation
